loading page

A cohort study of COVID-19 infection in pediatric oncology patients and the utility of remdesivir treatment
  • +9
  • Rina Yue Ling Ong,
  • Valerie Xue Fen Seah,
  • Chia-Yin Chong,
  • Koh Cheng Thoon,
  • Natalie Woon Hui Tan,
  • Jiahui Li,
  • Karen Donceras Nadua,
  • Shui Yen Soh,
  • Michaela Su-Fern Seng,
  • Thi Ngoc Anh Pham,
  • Chee Fu Yung,
  • Kai-Qian Kam
Rina Yue Ling Ong
KK Women's and Children's Hospital

Corresponding Author:[email protected]

Author Profile
Valerie Xue Fen Seah
KK Women's and Children's Hospital
Author Profile
Chia-Yin Chong
KK Women's and Children's Hospital
Author Profile
Koh Cheng Thoon
KK Women's and Children's Hospital
Author Profile
Natalie Woon Hui Tan
KK Women's and Children's Hospital
Author Profile
Jiahui Li
KK Women's and Children's Hospital
Author Profile
Karen Donceras Nadua
KK Women's and Children's Hospital
Author Profile
Shui Yen Soh
KK Women's and Children's Hospital
Author Profile
Michaela Su-Fern Seng
KK Women's and Children's Hospital
Author Profile
Thi Ngoc Anh Pham
KK Women's and Children's Hospital
Author Profile
Chee Fu Yung
KK Women's and Children's Hospital
Author Profile
Kai-Qian Kam
KK Women's and Children's Hospital
Author Profile

Abstract

Introduction Pediatric oncology patients are reportedly at risk for progression to severe Coronavirus disease-2019 (COVID-19) infection. Data on the safety and clinical effectiveness of remdesivir in children with cancer remains scarce. The main aims of this study were to describe COVID-19 infection in this cohort and to evaluate the utility of remdesivir treatment in terms of the time to viral clearance and its safety profile. Methods This was a retrospective observational cohort study of pediatric oncology patients ≤18 years of age with SARS-CoV-2 polymerase chain reaction (PCR) confirmed infection. Patients were admitted to KK Women’s and Children’s Hospital from 1 st November 2021 to 31 st March 2022. Clinical data, investigations and laboratory tests results were collected. Results Eighteen patients were included. Median age was 6.5 years (IQR: 4.64 – 9.83), and there were 13 males (72.2%). The immunosuppressive status of the cohort was: severe (n = 3, 22.2%), moderate (n = 9, 50.0%) and low (5, 27.8%). All patients had mild COVID-19 infection, and there were no COVID-19 attributed deaths. Remdesivir was initiated in four patients. We did not detect any benefit in terms of time to viral clearance or SARS-CoV2 PCR cycle threshold ≥25 between the treated versus non-treated groups. Remdesivir was well tolerated with no safety concerns. Conclusion Our cohort of immunocompromised pediatric oncology patients all had mild clinical COVID-19 with no directly attributable morbidity and mortality. In four patients, treatment with remdesivir was safe but did not lead to early viral clearance.